Literature DB >> 10482555

Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype.

R Skraban1, S Matthíasdóttir, S Torsteinsdóttir, G Agnarsdóttir, B Gudmundsson, G Georgsson, R H Meloen, O S Andrésson, K A Staskus, H Thormar, V Andrésdóttir.   

Abstract

Infectious molecular clones have been isolated from two maedi-visna virus (MVV) strains, one of which (KV1772kv72/67) is an antigenic escape mutant of the other (LV1-1KS1). To map the type-specific neutralization epitope, we constructed viruses containing chimeric envelope genes by using KV1772kv72/67 as a backbone and replacing various parts of the envelope gene with equivalent sequences from LV1-1KS1. The neutralization phenotype was found to map to a region in the envelope gene containing two deletions and four amino acid changes within 39 amino acids (positions 559 to 597 of Env). Serum obtained from a lamb infected with a chimeric virus, VR1, containing only the 39 amino acids from LV1-1KS1 in the KV1772kv72/67 backbone neutralized LV1-1KS1 but not KV1772kv72/67. The region in the envelope gene that we had thus shown to be involved in escape from neutralization was cloned into pGEX-3X expression vectors, and the resulting fusion peptides from both molecular clones were tested in immunoblots for reactivity with the KV1772kv72/67 and VR1 type-specific antisera. The type-specific KV1772kv72/67 antiserum reacted only with the fusion peptide from KV1772kv72/67 and not with that from LV1-1KS1, and the type-specific VR1 antiserum reacted only with the fusion peptide from LV1-1KS1 and not with that from KV1772kv72/67. Pepscan analysis showed that the region contained two linear epitopes, one of which was specific to each of the molecularly cloned viruses. This linear epitope was not bound by all type-specific neutralizing antisera, however, which indicates that it is not by itself the neutralization epitope but may be a part of it. These findings show that mutations within amino acids 559 to 597 in the envelope gene of MVV virus result in escape from neutralization. Furthermore, the region contains one or more parts of a discontinuous neutralization epitope.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482555      PMCID: PMC112822          DOI: 10.1128/JVI.73.10.8064-8072.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  Plasmas from lymphocyte- and macrophage-tropic SIVmac-infected macaques have antibodies with a broader spectrum of virus neutralization activity in macrophage versus lymphocyte cultures.

Authors:  W Zhuge; F Jia; I Adany; O Narayan; E B Stephens
Journal:  Virology       Date:  1997-01-06       Impact factor: 3.616

3.  In vivo and in vitro infection with two different molecular clones of visna virus.

Authors:  S Torsteinsdóttir; G Agnarsdóttir; S Matthíasdóttir; B Rafnar; V Andrésdóttir; O S Andrésson; K Staskus; G Pétursson; P A Pálsson; G Georgsson
Journal:  Virology       Date:  1997-03-17       Impact factor: 3.616

Review 4.  Visna-maedi in sheep.

Authors:  M Gudnadóttir
Journal:  Prog Med Virol       Date:  1974

5.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

6.  Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein.

Authors:  K H Siebelink; W Huisman; J A Karlas; G F Rimmelzwaan; M L Bosch; A D Osterhaus
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Change in tropism upon immune escape by human immunodeficiency virus.

Authors:  A McKnight; R A Weiss; C Shotton; Y Takeuchi; H Hoshino; P R Clapham
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Antigenic variation of SIV: mutations in V4 alter the neutralization profile.

Authors:  N E Kinsey; M G Anderson; T J Unangst; S V Joag; O Narayan; M C Zink; J E Clements
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Replication properties of dUTPase-deficient mutants of caprine and ovine lentiviruses.

Authors:  P Turelli; G Pétursson; F Guiguen; J F Mornex; R Vigne; G Quérat
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more
  17 in total

1.  Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.

Authors:  I Hötzel; W P Cheevers
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Propagating and detecting an infectious molecular clone of maedi-visna virus that expresses green fluorescent protein.

Authors:  Stefán R Jónsson; Valgerdur Andrésdóttir
Journal:  J Vis Exp       Date:  2011-10-09       Impact factor: 1.355

3.  Simultaneous mutations in CA and Vif of Maedi-Visna virus cause attenuated replication in macrophages and reduced infectivity in vivo.

Authors:  Bjarki Gudmundsson; Stefán Ragnar Jónsson; Oddur Olafsson; Gudrún Agnarsdóttir; Sigrídur Matthíasdóttir; Gudmundur Georgsson; Sigurbjorg Torsteinsdóttir; Vilhjálmur Svansson; Helga Bryndís Kristbjornsdóttir; Sigrídur Rut Franzdóttir; Olafur S Andrésson; Valgerdur Andrésdóttir
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Host range of small-ruminant lentivirus cytopathic variants determined with a selectable caprine arthritis- encephalitis virus pseudotype system.

Authors:  I Hötzel; W P Cheevers
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoprotein.

Authors:  S Valas; C Benoit; C Baudry; G Perrin; R Z Mamoun
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Domain Organization of Lentiviral and Betaretroviral Surface Envelope Glycoproteins Modeled with AlphaFold.

Authors:  Isidro Hötzel
Journal:  J Virol       Date:  2021-10-27       Impact factor: 6.549

7.  Evidence for recombination in the envelope gene of maedi-visna virus.

Authors:  Valgerdur Andrésdóttir
Journal:  Virus Genes       Date:  2003-08       Impact factor: 2.332

8.  Duplicated sequence motif in the long terminal repeat of maedi-visna virus extends cell tropism and is associated with neurovirulence.

Authors:  Thórdur Oskarsson; Hulda S Hreggvidsdóttir; Gudrún Agnarsdóttir; Sigrídur Matthíasdóttir; Margrét H Ogmundsdóttir; Stefán R Jónsson; Gudmundur Georgsson; Sigurdur Ingvarsson; Olafur S Andrésson; Valgerdur Andrésdóttir
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

9.  Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses.

Authors:  J D Trujillo; N M Kumpula-McWhirter; K J Hötzel; M Gonzalez; W P Cheevers
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Study of compartmentalization in the visna clinical form of small ruminant lentivirus infection in sheep.

Authors:  Hugo Ramírez; Ramsés Reina; Luigi Bertolotti; Amaia Cenoz; Mirna-Margarita Hernández; Beatriz San Román; Idoia Glaria; Ximena de Andrés; Helena Crespo; Paula Jáuregui; Julio Benavides; Laura Polledo; Valentín Pérez; Juan F García-Marín; Sergio Rosati; Beatriz Amorena; Damián de Andrés
Journal:  BMC Vet Res       Date:  2012-01-26       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.